Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SIEMENS HEALTHINEERS AG

(SHL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Siemens Healthineers bets on Varian to boost growth

11/17/2021 | 04:15am EST
FILE PHOTO: Siemens Healthineers headquarters is pictured in Erlangen

BERLIN (Reuters) - Shares in Siemens Healthineers rose on Wednesday after the German health group said it expected its newly-acquired Varian business to grow faster than other divisions in the coming three years, boosting the group's revenue.

Healthineers said revenue at Varian, the U.S. cancer treatment specialist it bought earlier this year in a $16.4 billion deal, should grow between 9% and 12% each year with operating return on sales rising to well over 20% until 2025.

The company raised its synergy targets from the Varian takeover to more than 350 million euros ($396 million) by 2025, from a previous goal of 300 million euros.

Shares in Healthineers were up 4.8% at 0822 GMT, topping the German blue-chip index.

It expects annual comparable revenue growth of 6%-8% between 2023 and 2025 for the group, up from the 5%-7% forecast it expected for the fiscal year 2022, excluding COVID-19 tests.

Earnings per share would rise 12%-15% each year between 2023 and 2025, it said, adding its dividend policy to distribute 50% to 60% of the net income would remain unchanged.

"With fiscal year 2022 we started the next chapter of strategy 2025," Chief Executive Bernd Montag told the company's Capital Markets Day.

Healthineers will focus more on fighting cancer, cardiovascular and neurovascular diseases, leveraging its market position in imaging and robotics.

($1 = 0.8842 euros)

(Reporting by Riham Alkousaa; Editing by Emma Thomasson and Edmund Blair)


ę Reuters 2021
All news about SIEMENS HEALTHINEERS AG
01/21SIEMENS HEALTHINEERS : Goldman Sachs raises its recommendation from Sell to Buy
MD
01/20SIEMENS HEALTHINEERS : Raised to Buy by Jefferies
MD
01/19SIEMENS HEALTHINEERS : Credit Suisse gives a Buy rating
MD
01/18Siemens AG - New strategic owner for Yunex Traffic
AQ
01/17SIEMENS HEALTHINEERS AG : Release of a capital market information
EQ
01/17SIEMENS HEALTHINEERS : Receives a Buy rating from JP Morgan
MD
01/13SIEMENS HEALTHINEERS : Gets a Buy rating from Deutsche Bank
MD
01/12SIEMENS HEALTHINEERS : JP Morgan reiterates its Buy rating
MD
01/11Siemens Capital software from Xcelerator Portfolio selected by Airbus for next generati..
AQ
01/11SIEMENS HEALTHINEERS : Kepler Cheuvreux remains Neutral
MD
More news
Analyst Recommendations on SIEMENS HEALTHINEERS AG
More recommendations
Financials
Sales 2022 20 048 M 22 741 M 22 741 M
Net income 2022 1 961 M 2 224 M 2 224 M
Net Debt 2022 11 746 M 13 323 M 13 323 M
P/E ratio 2022 33,9x
Yield 2022 1,56%
Capitalization 68 130 M 77 272 M 77 280 M
EV / Sales 2022 3,98x
EV / Sales 2023 3,71x
Nbr of Employees 66 000
Free-Float -
Chart SIEMENS HEALTHINEERS AG
Duration : Period :
Siemens Healthineers AG Technical Analysis Chart | SHL | DE000SHL1006 | MarketScreener
Technical analysis trends SIEMENS HEALTHINEERS AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 60,74 €
Average target price 70,71 €
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Bernhard Montag Chief Executive Officer
Jochen Schmitz Chief Financial Officer
Ralf Peter Thomas Chairman-Supervisory Board
Thorsten Opderbeck Head-Technology, Trade & Regional Media
A. Gregory Sorensen Member-Supervisory Board
Sector and Competitors